Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Senesco Technologies has contracted with VGXI to supply the plasmid portion of its combination therapy consisting of the Factor 5A gene and siRNA against Factor 5A.
Subscribe to our email newsletter
Senesco has previously reported positive preclinical in vivo results using its combination siRNA and plasmid against subcutaneous multiple myeloma tumors in immunodeficient mice.
Bruce Galton, president and CEO of Senesco, said: “VGXI’s manufacturing and technical expertise in producing plasmids for Senesco’s planned toxicology study and ultimately our clinical trial led us to choose them.”